Primary cells in BCR/FGFR1 positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib

ConclusionsThese results suggest that treatment with tyrosine kinase inhibitors may be beneficial for EMS patients during the search for a suitable stem cell donor and for those not eligible for transplantation.This article is protected by copyright. All rights reserved.

Source: European Journal of Haematology - September 1, 2017 Category: Hematology Authors: Niklas Landberg, Arta Dreimane, Marianne Rissler, Rolf Billstr öm, Helena Ågerstam Tags: Original Article Source Type: research